PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Baeten, Dominique
TI  - MEASURE 1: Secukinumab an Effective Treatment for Active AS
DP  - 2014  01
TA  - MD Conference Express
PG  - 18--18
VI  - 14
IP  - 51
4099  - http://mdc.sagepub.com/content/14/51/18.short
4100  - http://mdc.sagepub.com/content/14/51/18.full
AB  - Secukinumab, a high-affinity fully human monoclonal immunoglobulin G 1K antibody that selectively binds to and inhibits interleukin-17A, improves the signs and symptoms of active ankylosing spondylitis (AS). This article presents the results of the 16-Week Efficacy and 2-Year Long-term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis trial [MEASURE 1; NCT01358175], which evaluated intravenous loading and maintenance dosing of secukinumab.